BioSpace News Archive

Vifor Fresenius Medical Care Renal Pharma today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia ® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

Voyager Therapeutics, Inc. presented data validating the ability of novel capsids generated through its TRACER™ capsid discovery platform to consistently demonstrate desirable features such as improved blood-brain barrier penetration and increased transgene expression in multiple areas of the brain compared to conventional AAV capsids, as well as cross-species translation.

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present preclinical research showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.

Vektor Medical, pioneers of the world’s first technology to accurately map arrhythmias using only 12-lead ECG data, unveiled two studies further demonstrating clinical utility.

AdventHealth Tampa is proud to announce the accreditation of its new Obstetrics and Gynecology Residency Program, helping improve access to women’s healthcare in the Tampa Bay region.

The New England Journal of Medicine published detailed results from Eli Lilly and Company’s phase 2a study of peresolimab in rheumatoid arthritis, in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms.

BD (Becton, Dickinson and Company) announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate in the A.G.P. Virtual Healthcare Conference and host investor meetings.

ASLAN Pharmaceuticals today announced that it has dosed the first patient in a Phase 2a proof-of-concept study of farudodstat, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, in adult patients with severe alopecia areata (AA), an autoimmune condition causing hair loss.

Novartis Pharmaceuticals Canada Inc. is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal.